Outcomes of project dulce: A culturally specific diabetes management program

Annals of Pharmacotherapy

Volumn 39, Issue 5, 2005, Pages 817-822

  Gilmer, Todd P ^a   Philis Tsimikas, Athena ^b   Walker, Chris ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Whittier Institute for Diabetes   (United States)

Author keywords

Culturally sensitive; Diabetes; Disease management

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SULFONYLUREA;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CULTURAL FACTOR; DIABETES CONTROL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEALTH CENTER; HEMOGLOBIN DETERMINATION; HIGH RISK POPULATION; HOSPITAL RUNNING COST; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NURSING; PATIENT CARE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNITED STATES;

ANTIHYPERTENSIVE AGENTS; CALIFORNIA; CHOLESTEROL; COMMUNITY HEALTH SERVICES; COSTS AND COST ANALYSIS; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HISPANIC AMERICANS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAL INDIGENCY; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE);

EID: 17644412014     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E583     Document Type: Article

References (25)

1. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32.
2. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003;290:1884-90.
3. Diamant A, Babey S, Brown ER, Chawla N. Diabetes in California: findings from the 2001 California Health Interview Survey: UCLA Center for Health Policy Research, 2003.
4. Centers for Disease Control Task Force on Preventive Services, Diabetes Public Health Resource. 2003, National Center for Chronic Disease Prevention and Health Promotion, Atlanta, GA.
5. Norris SL, Nichols PJ, Caspersen CJ, Glasgow RE, Engelgau MM, Jack L, et al. The effectiveness of disease and case management for people with diabetes. A systematic review. Am J Prev Med 2002;22:15-38.
6. Norris SL, Engelgau MM, Narayan KM. Effectiveness of self-management training in type 2 diabetes: a systematic review of randomized controlled trials. Diabetes Care 2001;24:561-87.
7. Karlsen B, Idsoe T, Dirdal I, Rokne Hanestad B, Bru E. Effects of a group-based counselling programme on diabetes-related stress, coping, psychological well-being and metabolic control in adults with type 1 or type 2 diabetes. Patient Educ Couns 2004;53:299-308.
8. Sarkadi A, Rosenqvist U. Experience-based group education in type 2 diabetes: a randomised controlled trial. Patient Educ Couns 2004;53:291-8.
9. The California Medi-Cal Type 2 Diabetes Study. Closing the gap: effect of diabetes case management on glycemic control among low-income ethnic minority populations. Diabetes Care 2004;27:95-103.
10. Philis-Tsimikas A, Walker C, Rivard L, Talavera G, Reimann JO, Salmon M, et al. Improvement in diabetes care of underinsured patients enrolled in Project Dulce: a community-based, culturally appropriate, nurse case management and peer education diabetes care model. Diabetes Care 2004;27:110-5.
11. Mazze RS, Etzwiler DD, Strock E, Peterson K, McClave CR 2nd, Meszaros JF, et al. Staged diabetes management. Toward an integrated model of diabetes care. Diabetes Care 1994;17(suppl 1):56-66.
12. American Diabetes Association. Clinical practice recommendations for patients with diabetes mellitus. Diabetes Care 2004;27(suppl 1):S15-71.
13. Wagner EH, Sandhu N, Newton KM, McCulloch DK, Ramsey SD, Grothaus LC. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-9.
14. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA 1998;280:1490-6.
15. Sadur CN, Moline N, Costa M, Michalik D, Mendlowitz D, Roller S, et al. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care 1999;22:2011-7.
16. Diamant AL, Babey SH, Brown ER, Chawla N. Diabetes in California: nearly 1.5 million diagnosed and 2 million more at risk. Policy Brief UCLA Cent Health Policy Res 2003:1-8.
17. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ 2001;20:461-94.
18. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 1998;17:283-95.
19. Efron B, Tibshirani R. An introduction to the bootstrap. New York: Chapman & Hall, 1993:xvi, 436.
20. Institute of Medicine. Scientific opportunities and public needs: improving priority setting and public input at the National Institutes of Health. Washington, DC: National Academy Press, 1998.
21. Brown JB, Nichols GA, Glauber HS, Bakst AW. Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis. Diabetes Care 1999;22:1116-24.
22. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-80.
23. Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997;20:1396-402.
24. Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care 1997;20:1847-53.
25. Nau DP, Garber MC, Herman WH. The intensification of drug therapy for diabetes and its complications: evidence from 2 HMOs. Am J Managed Care 2004;10:118-23.